C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus
L. Paulowski, K. S. H. Beckham, M. D. Johansen, L. Berneking, N. Van, Y. Degefu, S. Staack, F. Vasquez Sotomayor, L. Asar, H. Rohde, B. B. Aldridge, M. Aepfelbacher, A. Parret, M. Wilmanns, L. Kremer, , F. P. Maurer
This study develops a C25-modified rifamycin derivative, 5j, which resists enzymatic inactivation by ArrMab and shows potent antimicrobial activity against M. abscessus in vitro and in macrophages.
bioRxiv · Jul 12, 2021Microbiology